Azenta, Inc. · NASDAQ:AZTA
Azenta — Q1 2025 Earnings Presentation
13 slides from Azenta's earnings presentation, Feb 5, 2025
Slide 1: Fiscal First Quarter 2025 Financial Results
Conference Call 1 Fiscal First Quarter 2025 Financial Results Fe b r u a r y 5 , 2 0 2 5 1 © 2025 Azenta, Inc. • All rights reserved
Slide 2: Safe Harbor Statement
Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co
Slide 3: Azenta Life Sciences Q1 2025 Financial Overview
Azenta Life Sciences Q1 2025 Financial Overview Continuing Operations – Quarter Ended December 31, 2024 Balance Sheet and Q1’25 Revenue (YoY) Profitability Capital Allocation • Revenue of $148M, 4% YoY growth on a • Non-GAAP EPS of $0.08 • Strong balance sheet with cash balance reported and organic
Slide 4: Azenta Operating Performance
Azenta Operating Performance Continuing Operations – Quarter Ended December 31, 2024 Total Azenta Organic Growth Q1’24 Revenue Growth (YtY) $ millions except EPS and percentages Non-GAAP $ millions Q1'24 Q1'25 YtY Az enta | Q1 '2 5 QTD Revenue 142 148 4% Gross profit 64 70 10% Q1Q1 '23 '2 4 Q1'24 Q1
Slide 5: Q1F 2025 Revenue Summary
Q1F 2025 Revenue Summary Organic unless otherwise noted Sample Management Solutions Sample Management Solutions 55% (“SMS”) • Growth of 5% in Sample Repository Solutions • $81 million • Growth of 8% in C&I and 3% in Stores • 3% YoY reported Systems • 2% YoY organic • $148 Million • 4% reported • 4%
Slide 6: Summary Consolidated Balance Sheet
Summary Consolidated Balance Sheet Quarter Ended December 31, 2024 Balance Sheet Q1’24 Revenue Growth (YtY) Highlights Sep Dec $ millions 2024 2024 QtQ • B Medical Systems assets Q1'24 Q1 '23 and liabilitiesYtY are Cash, restricted cash, short term marketable securities 433 466 32 Accounts receivabl
Slide 7: Summary Consolidated Cash Flow
Summary Consolidated Cash Flow Quarter Ended December 31, 2024 Cash Flow Q1’24 Revenue Growth (YtY) Highlights $ millions Q1'25 • $530M of cash,Q1 cash '23 equivalents, Q1'24 restricted YtY Cash, restricted cash and marketable securities - Beginning 522 Net income (13) cash and Reported marketable 1
Slide 8: Fiscal Year 2025 Guidance
Fiscal Year 2025 Guidance Continuing Operations Guidance, excluding B Medical Systems Metric FY’2025 Organic Growth: 3% to 5% YoY Revenue Multiomics: LSD Sample Management Solutions: MSD Adjusted 300bps of Adjusted EBITDA EBITDA margin expansion Other Interest Income:$16M - $18M Tax Rate: 27% - 29%
Slide 9: Appendix
Appendix 9 9 © 2025 Azenta, Inc. • All rights reserved
Slide 10: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions except EPS and percentages $ millions, except EPS Q1 F Y24 Q2 FY 24 Q3 F Y24 Q4 F Y24 F Y24 Q1 F Y25 Revenue 141.7 136.4 144.3 150.8 573.2 147.5 GAAP gross prof it 61.7 60.7 65.5 69.6 257.5 68.7 Gross profit margin 43.6%
Slide 11: GAAP to Non-GAAP Reconciliation – Segments
GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions except percentages $ millions, except EPS Q1 FY24 Q2 F Y24 Q3 F Y24 Q4 FY24 FY24 Q1 F Y25 Multiomics Revenue 62.7 62.2 63.6 66.0 254.6 66.3 Gross prof it 28.5 27.7 29.2 30.0 115.4 30.6 Gross profit margin 45.4% 44.6% 45.9% 4
Slide 12: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions Q1 FY24 Q2 F Y24 Q3 FY24 Q4 F Y24 FY24 Q1 FY25 Net income (15.7) (136.9) (6.6) (5.0) (164.2) (13.3) (Income) Loss from discontinued operations, net of tax 8.5 120.7 6.4 4.9 140.5 3.9 Net income (Loss) f rom cont inuing ope
Slide 13: Calculation of Non-GAAP Organic Revenue
Calculation of Non-GAAP Organic Revenue Continuing Operations Q1 F Y24 Q2 FY 24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Revenue 4% 2% 4% 6% 4% 4% Acquisitions/divestitures (1%) 0% 0% 0% 0% 0% Currency exchange rates (1%) 0% 1% (0%) 0% (0%) Organic revenue 2% 3% 4% 5% 4% 4% Q1 F Y24 Q2 FY 24 Q3 FY24 Q4 FY24 FY2